Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 Jul. 3];7(6):s291. Available from: https://skin.dermsquared.com/skin/article/view/2417